Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + Cisplatin + Vinorelbine in advanced NSCLC
NCT01109524Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2010
- Primary completion
- Sep 2012
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Jul 2010; status: completed.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01109524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01109524.